
Pratiksha I Thakore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11101658/publications.pdf Version: 2024-02-01



4

#	Article	IF	CITATIONS
1	Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology, 2015, 33, 510-517.	17.5	1,487
2	RNA-guided gene activation by CRISPR-Cas9–based transcription factors. Nature Methods, 2013, 10, 973-976.	19.0	1,105
3	In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science, 2016, 351, 403-407.	12.6	957
4	Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature Methods, 2015, 12, 1143-1149.	19.0	808
5	Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nature Communications, 2015, 6, 6244.	12.8	383
6	Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nature Methods, 2016, 13, 127-137.	19.0	341
7	Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients. Molecular Therapy, 2013, 21, 1718-1726.	8.2	160
8	RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nature Communications, 2018, 9, 1674.	12.8	123
9	Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes. Nature Immunology, 2021, 22, 216-228.	14.5	116
10	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nature Genetics, 2021, 53, 332-341.	21.4	112
11	Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases. Molecular Therapy, 2015, 23, 523-532.	8.2	100
12	Stem-like intestinal Th17 cells give rise to pathogenic effector TÂcells during autoimmunity. Cell, 2021, 184, 6281-6298.e23.	28.9	99
13	CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. Tissue Engineering - Part A, 2017, 23, 738-749.	3.1	68
14	Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nature Biotechnology, 2022, 40, 896-905.	17.5	44
15	Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain. ACS Synthetic Biology, 2015, 4, 689-699.	3.8	30
16	Role of Pericellular Matrix in Mesenchymal Stem Cell Deformation during Chondrogenic Differentiation. Cellular and Molecular Bioengineering, 2010, 3, 387-397.	2.1	15
17	Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors. Methods in Molecular Biology, 2016, 1338, 71-88.	0.9	8

18 Genome Engineering for Therapeutic Applications. , 2015, , 27-43.